dr. john seymour on the efficacy of abt-199 in high-risk cll
Published 10 years ago • 1.3K plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:05
dr seymour on the role of mutational profiling in cll
-
0:51
dr. seymour on role of ibrutinib in cll
-
14:31
side effects w/ acalabrutinib vs ibrutinib for chronic lymphocytic leukemia (cll) - dr. john seymour
-
1:50
dr. seymour on the 4-year update of the murano trial in cll
-
0:35
dr. john seymour discusses what cll patients can hope for in the future
-
13:19
side effects of acalabrutinib vs. ibrutinib in relapsed cll - dr. john seymour ash 2021
-
2:17
dr. john seymour discusses cll, depth of remission and updates from ash 2018
-
1:10
dr. seymour on shifting standards of care in cll
-
32:33
charles swanton - cancer evolution, immune evasion and metastasis
-
3:27
two rare diseases before age 20: chansen savakinus' story
-
7:37
chronic lymphocytic leukemia (cll) - mayo clinic
-
7:26
mutated vs. unmutated igvh cll as an indication of high-risk disease - dr. john seymour ash 2022
-
16:38
fixed-duration treatment of venetoclax combined with rituximab for cll - dr. john seymour ash 2021
-
2:37
the use of venetoclax in chronic lymphocytic leukaemia
-
1:18
preliminary results of a phase ib study combining abt-199 and obinutuzumab in cll
-
1:02
john seymour, mbbs, phd, on whether mrd is a valid endpoint when measuring treatment efficacy in cll
-
1:53
dr. seymour discusses the results of the prima study
-
2:01
prof john seymour talks to ten news about pbs listing of leukaemia drug
-
9:58
dr. graeme fraser - cll patient prognosis
-
5:03
deborah sims and john seymour – murano trial (cll)
-
32:13
indolent lymphoma updates - with professor john seymour. eha 2020
-
19:10
response to cll therapies after fixed-duration venetoclax - ash 2023 dr. john seymour